PAM, CLDN9, CHST6, SLC16A3, KDELR3, and CASP6 are regarded as biomarkers or prognosis genes in the signature, with reports revealing their expression in the areas of the prostate (Jimenez et al., 2001), endometrial lung adenocarcinoma (Wang Z.H. et al., 2019), Uveal Melanoma (Li et al., 2018), and gastric cancer (Wang Z. et al., 2019). This evidence concerns the gene PAM and uveal melanoma.